Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms - PubMed (original) (raw)
Review
Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms
Herman Waldmann et al. Immunol Rev. 2008 Jun.
Abstract
The challenge of harnessing tolerance as a therapeutic modality has been greatly influenced by dogmas dictating how self-tolerance comes about. Deletional strategies popularized from the classical work of Medawar and Owen have always demanded stringent attention to eliminating all antigen-reactive cells. This was always considered a tough call for the treatment of autoimmune disease, where the number of antigens and their identity were hard to predict. The finding, some 15 years ago, that therapeutic tolerance could be elicited with non-lytic CD4 monoclonal antibodies using regulatory T cells as major operatives has opened up a new dimension in exploiting tolerance mechanisms for drug minimization in transplantation and for providing short-term treatments for long-term benefit in allergy, autoimmunity, transplantation, and other immunopathological conditions. Resolution of the mechanisms underlying tolerance induced by CD4 co-receptor blockade have provided a general paradigm for how regulatory T cells might be directed to get the upper hand in preventing disease. They have also identified an unexpected role for tissues to contribute to their own protection.
Similar articles
- Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult.
Shizuru JA, Alters SE, Fathman CG. Shizuru JA, et al. Immunol Rev. 1992 Oct;129:105-30. doi: 10.1111/j.1600-065x.1992.tb01421.x. Immunol Rev. 1992. PMID: 1361179 Review. No abstract available. - Reprogramming the immune system using antibodies.
Graca L, Waldmann H. Graca L, et al. Methods Mol Biol. 2006;333:247-68. doi: 10.1385/1-59745-049-9:247. Methods Mol Biol. 2006. PMID: 16790855 Review. - Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.
Brusko TM, Putnam AL, Bluestone JA. Brusko TM, et al. Immunol Rev. 2008 Jun;223:371-90. doi: 10.1111/j.1600-065X.2008.00637.x. Immunol Rev. 2008. PMID: 18613848 Review. - The regulation of autoimmunity through CD4+ T cells.
Hutchings P, Parish N, O'Reilly L, Dawe K, Roitt IM, Cooke A. Hutchings P, et al. Autoimmunity. 1993;15 Suppl:21-3. doi: 10.3109/08916939309008856. Autoimmunity. 1993. PMID: 8105991 Review. - CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection.
Jiang S, Lechler RI. Jiang S, et al. Inflamm Allergy Drug Targets. 2006 Dec;5(4):239-42. doi: 10.2174/187152806779010981. Inflamm Allergy Drug Targets. 2006. PMID: 17168794 Review.
Cited by
- The contribution of B cells to transplantation tolerance.
Graca L. Graca L. J Clin Invest. 2020 Jul 1;130(7):3406-3408. doi: 10.1172/JCI138122. J Clin Invest. 2020. PMID: 32452836 Free PMC article. - Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.
Wang Y, Camirand G, Lin Y, Froicu M, Deng S, Shlomchik WD, Lakkis FG, Rothstein DM. Wang Y, et al. J Immunol. 2011 Mar 1;186(5):2809-18. doi: 10.4049/jimmunol.0903805. Epub 2011 Jan 26. J Immunol. 2011. PMID: 21270412 Free PMC article. - NPT088 reduces both amyloid-β and tau pathologies in transgenic mice.
Levenson JM, Schroeter S, Carroll JC, Cullen V, Asp E, Proschitsky M, Chung CH, Gilead S, Nadeem M, Dodiya HB, Shoaga S, Mufson EJ, Tsubery H, Krishnan R, Wright J, Solomon B, Fisher R, Gannon KS. Levenson JM, et al. Alzheimers Dement (N Y). 2016 Jul 14;2(3):141-155. doi: 10.1016/j.trci.2016.06.004. eCollection 2016 Sep. Alzheimers Dement (N Y). 2016. PMID: 29067301 Free PMC article. - CD73 and adenosine generation in the creation of regulatory microenvironments.
Regateiro FS, Cobbold SP, Waldmann H. Regateiro FS, et al. Clin Exp Immunol. 2013 Jan;171(1):1-7. doi: 10.1111/j.1365-2249.2012.04623.x. Clin Exp Immunol. 2013. PMID: 23199317 Free PMC article. Review. - Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.
Martin AJ, Clark M, Gojanovich G, Manzoor F, Miller K, Kline DE, Morillon YM, Wang B, Tisch R. Martin AJ, et al. JCI Insight. 2016 Oct 20;1(17):e87636. doi: 10.1172/jci.insight.87636. JCI Insight. 2016. PMID: 27777971 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous